33 C
Saturday, July 31, 2021
Home NEWS IISc researchers design ‘heat-tolerant’ Covid-19 vaccine candidate

IISc researchers design ‘heat-tolerant’ Covid-19 vaccine candidate

Researchers on the Indian Institute of Science (IISc) have designed a “heat-tolerant” Covid-19 vaccine candidate that may ease the requirement for a chilly chain for a vaccination programme. The design was just lately printed within the Journal of Biological Chemistry.

It is a protein subunit vaccine that makes use of part of the virus’ spike protein known as the receptor-binding area (RBD) — the half that permits the virus to attach with the host cell to enter it. It differs from different vaccine candidates being developed because it solely makes use of a selected a part of the RBD — a string of 200 amino acids, as a substitute of the whole spike protein. The researchers discovered that it was efficient in getting an immune response within the guinea pigs however remained secure at greater temperatures.

When examined on guinea pig fashions, the vaccine candidate triggered a powerful immune response.

Also Read: Covid-19 vaccine updates: Pfizer announcement offers glimmer of hope

The vaccine candidate remained secure for a month at 37°C, and freeze-dried variations might tolerate temperatures as excessive as 100°C. This shall be a boon for mass vaccination campaigns, particularly in lower-and middle-income nations, as costly cooling mechanisms wouldn’t be wanted to move the vaccine to distant areas.

Compared to newer sorts equivalent to mRNA vaccines, making a protein-based vaccine like this can be scaled up simply in India the place producers have been making related vaccines for many years.

The vaccine candidate was developed by a crew led by Raghavan Varadarajan from Molecular Biophysics Unit at IISc and Mynvax, a startup incubated at IISc.

“Now we have to get funds to take this forward to clinical development,” stated Varadarajan. This would come with security and toxicity research in rats together with course of growth and GMP manufacture of a medical trial batch earlier than they’re examined on people. “Those studies can cost about Rs 10 crores. Unless the government funds us, we might not be able to take it forward.”

Source link

Most Popular